Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors - Hong Kong Investor (EN)
{{banner.link_text}}
For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE00B4R5TH58

NAV
HKD 16.27
As of 2025/05/08

1-Day Change
HKD -0.09 (-0.55%)
 As of 2025/05/08

Morningstar Rating

As of 2025/03/31

Key investment risks:

  • The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
  • Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related

More

  • risks. In extreme market conditions, you may lose your entire investment.
  • The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
  • The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
  • Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

Portfolio Management

Andy Acker, CFA: Portfolio Manager
Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA: Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative Performance (%)
As of 2025/03/31
A2 HKD (Net) MSCI World Health Care NR Sector Equity Healthcare - OE
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2015/02/27
A2 HKD (Net) -4.58 0.70 -11.06 0.70 -5.98 8.33 55.91 72.90
MSCI World Health Care NR -2.27 5.26 -6.73 5.26 -1.69 7.23 60.86 100.13
Sector Equity Healthcare - OE -3.52 1.59 -8.60 1.59 -4.24 -4.07 30.60 48.14
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
Calendar Year Returns (%)
As of 2025/03/31
A2 HKD (Net) MSCI World Health Care NR Sector Equity Healthcare - OE
2024 2023 2022 2021 2020 Performance Inception
A2 HKD (Net) 1.18 5.47 -4.28 5.39 22.79 -4.00
MSCI World Health Care NR 0.60 3.81 -5.31 20.46 12.97 -0.36
Sector Equity Healthcare - OE -1.49 2.72 -13.82 7.70 19.94 -0.76
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.

Recommended holding period 5 Years

Example Investment: HKD 100,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs13,780 HKD14,410 HKD
Average return each year-86.22%-32.12%
UnfavourableWhat you might get back after costs76,570 HKD103,090 HKD
Average return each year-23.43%0.61%
ModerateWhat you might get back after costs105,190 HKD148,390 HKD
Average return each year5.19%8.21%
FavourableWhat you might get back after costs132,520 HKD195,870 HKD
Average return each year32.52%14.39%
There is currently insufficient data to provide a useful indication of past performance to investors.
Fee Information
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2024/12/31) 		2.39%
The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2025/03/31)
% of Fund
Eli Lilly & Co 9.41
UnitedHealth Group Inc 6.87
AstraZeneca PLC 4.00
Johnson & Johnson 3.59
Boston Scientific Corp 3.13
Abbott Laboratories 3.09
Sanofi SA 3.06
Amgen Inc 2.89
AbbVie Inc 2.83
Vertex Pharmaceuticals Inc 2.82
TOTAL 41.69
Portfolio holdings are subject to change without notice. 
Sector Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31
Regional Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
A gameplan for healthcare investing amid policy uncertainty
6 May 2025
Timely & Topical

A gameplan for healthcare investing amid policy uncertainty

These company characteristics could help investors win out over looming tariffs and federal funding cuts in the healthcare sector.

Read More

Global Perspectives: What’s next for booming weight-loss drugs
20 Mar 2025
Features & Outlooks

Global Perspectives: What’s next for booming weight-loss drugs

New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.

Read More

The case for healthcare stocks amid political uncertainty
18 Mar 2025
Timely & Topical

The case for healthcare stocks amid political uncertainty

The sector offers both traditionally defensive holdings and long-term growth potential that now looks attractively valued.

Read More

Choose region

Country

Language

What type of investor are you?